BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 8369162)

  • 1. Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41.
    Allaway GP; Ryder AM; Beaudry GA; Maddon PJ
    AIDS Res Hum Retroviruses; 1993 Jul; 9(7):581-7. PubMed ID: 8369162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
    D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
    AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
    Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
    J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of human immunodeficiency virus neutralizing antibodies using fusion complexes.
    Zipeto D; Matucci A; Ripamonti C; Scarlatti G; Rossolillo P; Turci M; Sartoris S; Tridente G; Bertazzoni U
    Microbes Infect; 2006 May; 8(6):1424-33. PubMed ID: 16702010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.
    Richardson TM; Stryjewski BL; Broder CC; Hoxie JA; Mascola JR; Earl PL; Doms RW
    J Virol; 1996 Feb; 70(2):753-62. PubMed ID: 8551612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates.
    Stamatatos L; Lim M; Cheng-Mayer C
    AIDS Res Hum Retroviruses; 2000 Jul; 16(10):981-94. PubMed ID: 10890360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1.
    Armstrong SJ; McInerney TL; McLain L; Wahren B; Hinkula J; Levi M; Dimmock NJ
    J Gen Virol; 1996 Dec; 77 ( Pt 12)():2931-41. PubMed ID: 9000083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
    Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
    Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.
    Park EJ; Vujcic LK; Anand R; Theodore TS; Quinnan GV
    J Virol; 1998 Sep; 72(9):7099-107. PubMed ID: 9696803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multifaceted consequences of anti-gp41 monoclonal antibody 2F5 binding to HIV type 1 virions.
    Neurath AR; Strick N; Lin K; Jiang S
    AIDS Res Hum Retroviruses; 1995 Jun; 11(6):687-96. PubMed ID: 7576928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion.
    Finnegan CM; Berg W; Lewis GK; DeVico AL
    J Virol; 2002 Dec; 76(23):12123-34. PubMed ID: 12414953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies.
    Burkly L; Mulrey N; Blumenthal R; Dimitrov DS
    J Virol; 1995 Jul; 69(7):4267-73. PubMed ID: 7769687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression.
    Zwart G; van der Hoek L; Valk M; Cornelissen MT; Baan E; Dekker J; Koot M; Kuiken CL; Goudsmit J
    Virology; 1994 Jun; 201(2):285-93. PubMed ID: 7514319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of endoproteolytic cleavage and intracellular transport of human immunodeficiency virus type 1 envelope glycoproteins using mutant CD4 molecules bearing the transmembrane endoplasmic reticulum retention signal.
    Raja NU; Vincent MJ; Jabbar MA
    J Gen Virol; 1993 Oct; 74 ( Pt 10)():2085-97. PubMed ID: 8409933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.
    McCaffrey RA; Saunders C; Hensel M; Stamatatos L
    J Virol; 2004 Apr; 78(7):3279-95. PubMed ID: 15016849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site.
    Vijh-Warrier S; Pinter A; Honnen WJ; Tilley SA
    J Virol; 1996 Jul; 70(7):4466-73. PubMed ID: 8676471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of primary human immunodeficiency virus type 1 envelope glycoprotein-mediated entry by human antibodies.
    Schutten M; Andeweg AC; Rimmelzwaan GF; Osterhaus AD
    J Gen Virol; 1997 May; 78 ( Pt 5)():999-1006. PubMed ID: 9152416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates.
    Pinter A; Honnen WJ; Racho ME; Tilley SA
    AIDS Res Hum Retroviruses; 1993 Oct; 9(10):985-96. PubMed ID: 7506556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.